Skip to main content
Caplight Logo









AAVINUE

AAVINUE

Private
Sudbury, MassachusettsHealthcare & Life Scienceshttps://aavinue.com/

Last Round

Accelerator

Dec 13, 2023

Company Overview

AAVINUE operates in Healthcare & Life Sciences and is based in Sudbury, Massachusetts. Its latest recorded funding round was an Accelerator round in December 2023.

AAVINUE is a biotechnology company developing a non-viral gene delivery technology based on a proprietary mini-nucleosome platform to treat genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

AAVINUE Comparables

Compare AAVINUE with similar companies based on industry and business-model similarity.

AAVINUE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mediphage Bioceuticals
87%
Code Biotherapeutics
86%
Anjarium Biosciences
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

AAVINUE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorDec 13, 2023
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

AAVINUE Investors

Notable investors and investment history

AAVINUE investors
InvestorRounds
Massachusetts Biomedical InitiativesAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 13, 2023

    Received funding from Massachusetts Biomedical Initiatives.

Book a demo to see all signals

For institutional investors. Book with your work email.

AAVINUE Filings

Explore SEC and related filing metadata, where available.

AAVINUE filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about AAVINUE's valuation, stock price, and market status.

Is AAVINUE a public or private company?

AAVINUE is a private company.

What is the current stock price of AAVINUE?

AAVINUE is a private company, so its shares have no public market price. Caplight tracks AAVINUE's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is AAVINUE worth (valuation)?

Valuation information for AAVINUE is not publicly available.

Can I buy AAVINUE stock?

AAVINUE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was AAVINUE's last funding round?

AAVINUE's most recent funding round was Accelerator on December 13, 2023.

Who are the main investors in AAVINUE?

Key investors in AAVINUE include Massachusetts Biomedical Initiatives.

Will AAVINUE IPO soon?

No public IPO plans have been announced for AAVINUE.

How can I track AAVINUE secondary market activity?

Caplight tracks bids, offers, and trades in AAVINUE's shares on secondary markets.

Firmographic Details

HeadquartersSudbury, Massachusetts
Year Founded2023
Last FundingDec 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?